slotkoers
Korea S.E.
00:00:00 10-05-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
21.400
KRW
|
+0,23%
|
|
-3,60%
|
-22,18%
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
725.681
|
761.628
|
703.085
|
652.094
|
1.347.135
|
1.351.191
|
Bedrijfswaarde
1 |
568.991
|
594.231
|
575.452
|
515.826
|
1.206.656
|
1.218.468
|
K/w-verhouding
|
44
x
|
27,2
x
|
22,5
x
|
25,8
x
|
98,7
x
|
33,8
x
|
Dividendrendement
|
1,69%
|
3,66%
|
2,79%
|
3,46%
|
1,97%
|
-
|
Marktkapitalisatie/omzet
|
14,2
x
|
11,8
x
|
11,7
x
|
11
x
|
19,5
x
|
17,1
x
|
Bedrijfswaarde/omzet
|
11,1
x
|
9,18
x
|
9,54
x
|
8,73
x
|
17,5
x
|
15,4
x
|
Bedrijfswaarde/EBITDA
|
26,2
x
|
15,9
x
|
16,9
x
|
17,1
x
|
32,6
x
|
26,9
x
|
Bedrijfswaarde/FCF
|
43,4
x
|
10
x
|
-81,4
x
|
26,5
x
|
72,4
x
|
200
x
|
FCF Yield
|
2,31%
|
9,96%
|
-1,23%
|
3,77%
|
1,38%
|
0,5%
|
Price to Book
|
3,52
x
|
3,51
x
|
3,43
x
|
3,11
x
|
6,24
x
|
5,94
x
|
Aantal aandelen (in duizenden)
|
51.176
|
49.780
|
49.030
|
49.030
|
49.130
|
49.134
|
Referentieprijs
2 |
14.180
|
15.300
|
14.340
|
13.300
|
27.420
|
27.500
|
Datum van publicatie
|
18-03-19
|
06-04-20
|
19-03-21
|
18-03-22
|
14-03-23
|
11-03-24
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
51.211
|
64.699
|
60.295
|
59.088
|
69.098
|
79.210
|
EBITDA
1 |
21.703
|
37.445
|
34.062
|
30.145
|
37.053
|
45.342
|
Bedrijfsresultaat (EBIT)
1 |
19.744
|
35.375
|
31.978
|
28.109
|
33.603
|
40.360
|
Operationele Marge
|
38,55%
|
54,68%
|
53,04%
|
47,57%
|
48,63%
|
50,95%
|
Resultaat voor belastingen (EBT)
1 |
22.486
|
38.921
|
36.084
|
33.581
|
34.457
|
49.572
|
Nettowinst (verlies)
1 |
16.491
|
28.070
|
31.478
|
25.318
|
27.267
|
39.930
|
Nettomarge
|
32,2%
|
43,39%
|
52,21%
|
42,85%
|
39,46%
|
50,41%
|
WPA
2 |
322,5
|
562,7
|
638,6
|
516,4
|
277,8
|
813,0
|
Free Cash Flow
1 |
13.123
|
59.179
|
-7.069
|
19.460
|
16.675
|
6.080
|
FCF-marge
|
25,63%
|
91,47%
|
-11,72%
|
32,93%
|
24,13%
|
7,68%
|
Kasstroomconversie (ebitda)
|
60,47%
|
158,04%
|
-
|
64,56%
|
45%
|
13,41%
|
Kasstroomconversie (nettowinst)
|
79,58%
|
210,83%
|
-
|
76,86%
|
61,16%
|
15,23%
|
Dividend per aandeel
2 |
240,0
|
560,0
|
400,0
|
460,0
|
540,0
|
-
|
Datum van publicatie
|
18-03-19
|
06-04-20
|
19-03-21
|
18-03-22
|
14-03-23
|
11-03-24
|
Fiscaal tijdperk: december |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Omzet
1 |
24,67
|
18,38
|
18,72
|
17,44
|
EBITDA
|
-
|
-
|
-
|
-
|
Bedrijfsresultaat (EBIT)
1 |
12,52
|
7,636
|
9,875
|
10,34
|
Operationele Marge
|
50,77%
|
41,54%
|
52,76%
|
59,3%
|
Resultaat voor belastingen (EBT)
|
-
|
-
|
-
|
-
|
Nettowinst (verlies)
1 |
-
|
7,439
|
9,8
|
8,544
|
Nettomarge
|
-
|
40,47%
|
52,36%
|
48,99%
|
WPA
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
04-05-23
|
09-08-23
|
10-11-23
|
05-02-24
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
156.690
|
167.398
|
127.633
|
136.268
|
140.479
|
132.724
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
13.123
|
59.179
|
-7.069
|
19.460
|
16.675
|
6.080
|
ROE (netto-inkomsten/eigen vermogen)
|
7,83%
|
13,3%
|
14,9%
|
12,1%
|
12,8%
|
18%
|
ROA (netto-inkomsten/totale activa)
|
5,6%
|
9,81%
|
8,91%
|
7,93%
|
9,11%
|
10,5%
|
Totale activa
1 |
294.510
|
286.155
|
353.123
|
319.449
|
299.157
|
380.974
|
Nettoactief per aandeel
2 |
4.032
|
4.359
|
4.184
|
4.277
|
4.396
|
4.626
|
Cashflow per aandeel
2 |
344,0
|
436,0
|
326,0
|
454,0
|
105,0
|
642,0
|
Capex
1 |
2.276
|
6.159
|
21.080
|
3.888
|
1.544
|
8.155
|
Capex/omzet
|
4,44%
|
9,52%
|
34,96%
|
6,58%
|
2,24%
|
10,3%
|
Datum van publicatie
|
18-03-19
|
06-04-20
|
19-03-21
|
18-03-22
|
14-03-23
|
11-03-24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| -22,18% | 768 mln. | | +19,62% | 43,27 mld. | | +24,52% | 22,92 mld. | | +20,29% | 15,43 mld. | | +7,48% | 12,95 mld. | | +42,51% | 11,83 mld. | | -8,84% | 6,91 mld. | | -0,05% | 6,79 mld. | | -8,87% | 5,73 mld. | | +13,13% | 5,55 mld. |
Generieke geneesmiddelen
|